Thomas Rossi

Thomas Rossi

Company: Venthera

Job title: Chief Executive Officer


PI3K Inhibitors for the Treatment of Venous and Lymphatic Malformations via Topical Formulations 1:00 pm

• Many cutaneous VMs and LMs are driven by mutations in PI3K or its upstream driver, TIE2 • Venthera are currently developing a topical PI3K inhibitor in order to safely and effectively treat these lesions at their sourceRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.